Full history for every metric is available with a Kvantra account
NovaBay Pharmaceuticals, Inc. (NBY)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 10 | 10 | 14 | 10 | 10 | 0 | 2 |
| Operating profit | $m | -8 | - | |||||
| Net profit | $m | -11 | -6 | -11 | -10 | -7 | -22 | - |
| EPS reported | $ | -3.80 | - | |||||
| Operating cashflow per share | $ | -1.45 | -0.38 | |||||
| Capex per share | $ | 0.00 | 2.48 | |||||
| FCF per share | $ | -1.45 | 2.10 | |||||
| Free cash flow | $m | -8 | 65 | |||||
| Net debt | $m | -8 | -7 | |||||
| Book value equity | $m | -23 | - | |||||
| Book value per share | $ | -3.92 | - | |||||
| Number of shares | m | 5.82 | 31.05 | |||||
| DPS (TTM paid) | $ | 4.00 | 4.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -7.19 | 0.36 | |||||
| P/S LTM | x | 0.00 | 15.89 | |||||
| P/FCF LTM | x | -19.47 | 0.60 | |||||
| EV/EBITDA LTM | x | -21.08 | -0.74 | |||||
| EV/Sales LTM | x | 0.00 | 13.06 | |||||
| Earnings Yield LTM | % | -13.49% | 1059.3% | |||||
| FCF Yield | % | -5.14% | 166.28% | |||||
| Quality | ||||||||
| ROE | % | 97.00% | 789.69% | |||||
| ROIC | % | -90.49% | -34.47% | |||||
| Operating margin | % | 0.00% | -1780.7% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | 2642.1% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | -48.15% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 2.93% | 272.13% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -21.78% | -7.72% | |||||
| FCF/Debt | x | -10.86 | - | |||||
| Net Debt/EBITDA | x | 0.96 | 0.16 | |||||
| EBIT/Net interest | x | -27.38 | 843.44 | |||||
| Net debt/market cap | % | -4.81% | -17.80% | |||||
| Net debt/Equity | x | 0.35 | - | |||||
| Gross debt/equity | x | -0.03 | - | |||||
Company overview
NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free